Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Kenya's economy faces climate change risks: World Bank
-
India's cows offer biogas alternative to Mideast energy crunch
-
Crude edges up after wild swing, stocks track Wall St rally
-
New Princess Diana documentary promises her own words
-
Oil slumps after hitting peak, US indices reach new records
-
Venezuela leader hikes minimum wage package by 26%
-
Apple earnings beat forecasts on iPhone 17 demand
-
Bangladesh signs biggest-ever plane deal for 14 Boeings
-
Musk grilled on AI profits at OpenAI trial
-
Venezuela opens arms to world with Miami-Caracas flight
-
US Congress votes to end record government shutdown
-
First direct US-Venezuela flight in years arrives in Caracas
-
Just telling nations to quit fossil fuels 'not realistic': COP31 chief
-
Trump hails 'greatest king' Charles as state visit wraps up
-
Drivers help study road-trip mystery: what became of bug splats?
-
Oil strikes 4-year peak, stocks rise
-
Iran's supreme leader defies US blockade as oil prices soar
-
White House against Anthropic expanding Mythos model access: report
-
Oil crisis fuels calls to speed up clean energy transition
-
European rocket blasts off with Amazon internet satellites
-
Nigerian airlines avert shutdown as Mideast war hikes fuel prices
-
ArcelorMittal boosts sales but profits squeezed
-
German growth beats forecast but energy shock looms
-
Air France-KLM trims 2026 outlook over Middle East war impact
-
Oil surges 7% to top $126 on Trump blockade warning
-
Volkswagen warns of more cost cuts as profits plunge
-
Rolls-Royce confident on profits despite Mideast war disruption
-
French economy records zero growth in first quarter
-
Carmaker Stellantis swings back into profit as sales climb
-
Trump warns Iran blockade could last months, sending oil prices soaring
-
Denmark's Soren Torpegaard Lund to 'stay true' at Eurovision
-
Mamdani calls on King Charles to return Koh-i-Noor diamond
-
Key points from the first global talks on phasing out fossil fuels
-
Cuban boy's sporting dreams on hold as surgery backlog grows
-
Bali drowning in trash after landfill closed
-
ECB set to hold rates despite Iran war energy shock
-
Samsung Electronics posts record quarterly profit on AI boom
-
OMP Ranked in Highest Two Across All Four Use Cases in the 2026 Gartner(R) Critical Capabilities for Supply Chain Planning Solutions: Process Industries
-
Meta chief Zuckerberg doubles down on AI spending
-
Google-parent Alphabet soars as Meta stumbles over AI costs
-
Brazil lowers benchmark rate to 14.5% in second consecutive cut
-
Google-parent Alphabet soars as rivals stumble over AI costs
-
Anti-Bezos campaign urges Met Gala boycott in New York
-
African oil producers defend need to drill at fossil fuel exit talks
-
'Gritty' Philadelphia pitches itself as low-cost US World Cup choice
-
'I literally was a fool': Musk grilled in OpenAI trial
-
OpenAI facing 'waves' of US lawsuits over Canada mass shooting
-
Ticket price hikes not affecting summer air travel demand: IATA
-
Uber adds hotel booking in push to become 'everything app'
-
Oil spikes while stocks slip ahead of US Fed rate decision
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
H.Meyer--CPN